Drug Trial Radar · NCT07189910
Sequential rhTPO and Eltrombopag Following Glucocorticoids for Severe Adult ITP
Last checked: Nov 20, 2026Latest source record: Sep 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Dec 1, 2025
Primary completion
Nov 1, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To address the clinical need for improving early response rates, maintaining sustained responses, reducing relapse rates, and minimizing adverse events in the treatment of immune thrombocytopenia (ITP), the investigators developed a comprehensive in-hospital and post-discharge management strategy. In this study, hospitalized participants will receive a 14-day regimen of high-dose dexamethasone (HD-DXM) plus recombinant human thrombopoietin (rhTPO), followed by a 10-week course of oral eltrombopag olamine dry suspension after discharge. The investigators aim to evaluate the efficacy and safety of this sequential treatment strategy in adult ITP patients.
Conditions
- Primary Immune Thrombocytopenia (ITP)
Interventions
EltrombopagDrug
Participants assigned to the observation group will be treated with eltrombopag oral suspension (EPAG-pfos).
PlaceboOther
Participants in the control group will receive a placebo at the same dose, instead of eltrombopag oral suspension (EPAG-pfos).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sustained response rate (SRR) at 3 months of treatment.Time frame: 3 months of the study
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Wuhan Union Hospital
Wuhan, Hubei, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.